American Society of Clinical Oncology, Inc. (ASCO®) and the Conquer Cancer Foundation® (CCF) continue to recognize the donors whose generous contributions are making the vision of CancerLinQTM a reality. In this latest installment, ASCO® and CCF recognize returning donors who have contributed to CancerLinQTM more than once.
Genentech, Novartis Oncology, and Susan G. Komen®, represent a dedicated donor group that is committed to the development of CancerLinQTM, a powerful platform containing growing amounts of real-world cancer information can provide new tools to provide quality care.
Genentech, a member of the Roche Group, is a world leader in biotechnology. Genentech's commitment to improving cancer care inspired the organization's continuous support of CancerLinQTM.
"CancerLinQTM has the potential to generate insights from real-world care that are difficult or would take years to collect through traditional clinical trials, population based studies, or registries," said Dr. Bishop. "This tool should be leveraged by all stakeholders, including oncology professionals, patients, payers, manufacturers and policymakers. The ultimate goal is to improve the care of people with cancer, and we believe ASCO is uniquely positioned to bring all relevant stakeholders together to achieve this goal."
Novartis Oncology's commitment to providing caregivers with the tools and knowledge needed to deliver the highest quality of care inspired its ongoing support of CancerLinQTM. Much of Novartis Oncology's work focuses precision oncology and an evolving understanding of how cancers develop on a genomic level. Novartis Oncology believes that CancerLinQTM has the potential to address the current challenges encountered during this process.
"In the months and years to come, digital health will play a large role in how we treat cancer and may ultimately lead to better outcomes for cancer patients," said Bill Hinshaw, Head, US Oncology. "CancerLinQ'sTM ability to uncover patterns related to patient characteristics, treatments and outcomes that can ultimately help lead to improvements in care address a common goal for the entire cancer community."
Susan G. Komen®
As one of the earliest stakeholders in CancerLinQTM, Susan G. Komen® has worked with ASCO and the Conquer Cancer Foundation over many years to further efforts in quality care and big data to generate patient-specific treatment. CancerLinQTM lends to Komen's mission to save lives and end breast cancer forever by empowering others, ensuring quality care for all.
“As we continue to integrate big data and tools like CancerLinQTM into cancer care, we foresee a great opportunity to incorporate information from, and share information with, community oncologists, many of whom care for patients from underserved or under-represented populations and/or work in areas of the country that may not have a major cancer center nearby," said Judith A. Salerno, M.D., M.S., Komen President and CEO.
CancerLinQTM is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncologyTM; HELSINN; Janssen Oncology; Lilly; Novartis Oncology; Pfizer Oncology; Raj Mantena, RPh; Susan G. Komen®; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva.
CancerLinQTM is developed by CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®). To join in supporting CancerLinQTM, please donate to the Conquer Cancer Foundation or email email@example.com for more information.